Clinical trial · Observational
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
Real-world Analysis of Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Tumour, Residual | Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Timing of drug administration | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- combined well responder
- description
- Both primary tumor and nodal response achieve major pathological response (MPR).
- interventionNames
- Drug: Timing of drug administration
- label
- poor responder
- description
- Primary tumor or/and nodal response can not achieve MPR.
- interventionNames
- Drug: Timing of drug administration
Primary outcomes (1)
- measure
- Event-free survival
- timeFrame
- At least one year
- description
- the time from diagnosis to any progression of disease precluding surgery, progression or recurrence of disease after surgery or death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with stage III NSCLC who received neoadjuvant immunochemotherapy. * early-stage NSCLC patients who were initially unresectable. * 18 years of age or older. * Karnofsky performance status (KPS) score of 100 or 90. Exclusion Criteria: * Patients with stage IV NSCLC * Patients with known ALK translocations or EGFR mutations. * Karnofsky performance status (KPS) score \<90.
References
Publications (0)
Data not yet available